Skip to main content
CellSeed Inc. logo

CellSeed Inc. — Investor Relations & Filings

Ticker · 7776 ISIN · JP3423530009 T Manufacturing
Open in API
Filings indexed 65 across all filing types
Latest filing 2024-03-28 Governance Information
Country JP Japan
Listing T 7776

About CellSeed Inc.

https://www.cellseed.com/en/

CellSeed Inc. is a regenerative medicine company centered on the research, development, and commercialization of its proprietary "cell sheet engineering" technology. This innovative platform enables the creation and harvesting of intact sheets of cultured cells without enzymatic treatment, preserving the extracellular matrix and cell-to-cell junctions critical for therapeutic efficacy. The company's business is structured around three core activities: the development of its own pipeline of cell sheet-based therapies for tissue regeneration, the sale of specialized temperature-responsive cell cultureware and related equipment, and the provision of contract development and manufacturing (CDMO) services for regenerative medicine products.

Recent filings

Filing Released Lang Actions
内部統制報告書－第23期(2023/01/01－2023/12/31)
Governance Information Classification · 1% confidence The document is explicitly titled "内部統制報告書" (Internal Control Report) in the header and within the table structure. It references the legal basis as "金融商品取引法第24条の４の４第１項" (Financial Instruments and Exchange Act Article 24-4-4, Paragraph 1), which mandates the filing of an Internal Control Report by listed companies in Japan. The content discusses the framework, scope, criteria, and conclusion regarding the assessment of internal controls over financial reporting as of the fiscal year-end (2023年12月31日). This directly corresponds to the requirements for an Audit Report / Information filing, specifically concerning internal controls, which aligns best with the 'AR' (Audit Report / Information) category, as it is a formal report on internal control effectiveness, distinct from a full Annual Report (10-K) or a simple Earnings Release (ER).
2024-03-28 Japanese
有価証券報告書－第23期(2023/01/01－2023/12/31)
Annual Report Classification · 1% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains detailed financial statements, business indicators, and management information for the fiscal year ending December 31, 2023. The document is clearly a comprehensive annual filing rather than an announcement or a summary. FY 2023
2024-03-28 Japanese
確認書
Report Publication Announcement Classification · 1% confidence The document text contains the title "第３四半期報告書" (Third Quarter Report) and specifies the period covered: "第23期第３四半期（自 2023年７月１日 至 2023年９月30日）". It is a formal document submitted to the Kanto Local Finance Bureau ("関東財務局長") under the Financial Instruments and Exchange Act. This structure and content strongly indicate a comprehensive financial report for an interim period shorter than a year, which aligns with the definition of an Interim / Quarterly Report (IR). Although it is a confirmation document related to the report, the core subject matter is the quarterly financial reporting itself, making IR the most appropriate classification over a general RPA or RNS, especially given its comprehensive nature implied by the context of a 'Quarterly Report' submission.
2023-11-14 Japanese
四半期報告書－第23期第3四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (四半期報告書) for the third quarter of the fiscal year 2023, filed by CellSeed Inc. with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements (balance sheet, income statement) and management analysis for the period ending September 30, 2023. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-14 Japanese
確認書
Report Publication Announcement Classification · 1% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically related to the accuracy of the Second Quarter Report (Interim Report). While it references the quarterly report, the document itself is a formal regulatory filing confirming the validity of the financial statements, which is a standard component of Japanese regulatory reporting requirements. Given the specific nature of this confirmation document, it falls under the general regulatory filing category.
2023-08-14 Japanese
四半期報告書－第23期第2四半期(2023/04/01－2023/06/30)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (四半期報告書) for the second quarter of the 23rd fiscal period (April 1, 2023, to June 30, 2023) for CellSeed Inc. It contains detailed financial statements, management analysis (MDA), and business status updates, which are characteristic of an Interim/Quarterly Report. It is not a mere announcement or certification, as it provides comprehensive financial data. H1 2023
2023-08-14 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.